Actinium reports Phase II data for Actimab-A in AML

Actinium Pharmaceuticals Inc. (NYSE-M:ATNM) reported preliminary data from 13 evaluable patients ages 60 and older with newly diagnosed acute myelogenous

Read the full 209 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE